The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker, which hopes to transform the market by offering patients a noninjectable treatment.
from Yahoo News - Latest News & Headlines https://ift.tt/2ABqa4O
No comments:
Post a Comment